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Abstract
Background: We previously reported risk haplotypes for two genes related with serotonin and
dopamine metabolism: MAOA in migraine without aura and DDC in migraine with aura. Herein we
investigate the contribution to migraine susceptibility of eight additional genes involved in dopamine
neurotransmission.
Methods: We performed a two-stage case-control association study of 50 tag single nucleotide
polymorphisms (SNPs), selected according to genetic coverage parameters. The first analysis
consisted of 263 patients and 274 controls and the replication study was composed by 259 cases
and 287 controls. All cases were diagnosed according to ICHD-II criteria, were Spanish Caucasian,
and were sex-matched with control subjects.
Results: Single-marker analysis of the first population identified nominal associations of five genes
with migraine. After applying a false discovery rate correction of 10%, the differences remained
significant only for DRD2 (rs2283265) and TH (rs2070762). Multiple-marker analysis identified a
five-marker T-C-G-C-G (rs12363125-rs2283265-rs2242592-rs1554929-rs2234689) risk haplotype
in DRD2 and a two-marker A-C (rs6356-rs2070762) risk haplotype in TH that remained significant
after correction by permutations. These results, however, were not replicated in the second
independent cohort.
Conclusion: The present study does not support the involvement of the DRD1, DRD2, DRD3,
DRD5, DBH, COMT, SLC6A3 and TH genes in the genetic predisposition to migraine in the Spanish
population.
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Background
Migraine is a highly prevalent neurological disorder
involving multiple susceptibility genes and environmen-
tal factors [1,2]. The current clinical classification follows
the International Criteria for Headache Disorders (ICHD-
II), with the two main categories of migraine without aura
(MO) and migraine with aura (MA) [3]. The pathophysi-
ology of migraine is not entirely understood, but a role for
dopamine (DA) was already suggested thirty years ago [4].
The DA hypothesis relies on the observed signs of central
DA hypersensitivity in migraine patients and the known
capacity of DA receptors to regulate nociception, vascular
tone and autonomic responses [5]. Studies in animal
models revealed that DA receptors are present in the
trigeminovascular pathway and showed that DA can act as
an inhibitor of nociceptive trigeminovascular transmis-
sion in the rat brain [6]. Along this line, DA antagonists
have proved useful in aborting migraine headache or
associated symptoms [5]. However, DA antagonists are
not always selective and may act through DA receptor-
independent mechanisms [7]. Also, a review of pharma-
cological and therapeutic studies in migraine could not
provide convincing evidence of a direct role of DA in
migraine pathogenesis [8].
Several association studies in different populations have
focused on genes encoding proteins of the dopaminergic
neurotransmission system, including DA receptors, the
DA transporter, and enzymes involved in the synthesis
and catabolism of DA. These studies provided conflicting
results [7], although a recent, most comprehensive analy-
sis of 10 dopamine-related genes in MA suggested that
DBH and SLC6A3, at least, might be involved in migraine
pathogenesis [9].
In a previous study that evaluated the contribution of 19
serotonin-related genes to migraine susceptibility in our
cohort of Spanish migraineurs, we reported risk haplo-
types in MAOA for migraine without aura and in DDC for
migraine with aura [10], both genes being key players in
the serotonin and dopamine metabolic pathways. In
order to further elucidate the involvement of the
dopaminergic system in migraine liability, nine
dopamine-related genes were selected for a two-stage case-
control association study in the Spanish population.
Methods
Subjects
Our initial sample (population 1) was recruited between
2002 and 2006 in Spain and consisted of 271 migraineurs
(mean age 37 +/- 16 years) and 285 unrelated migraine-
free controls (mean age 55 +/- 18) matched for ethnicity
(Caucasian Spanish) and sex frequency (76% women).
The follow-up replication study (population 2) consisted
of 272 patients and 302 healthy controls recruited subse-
quently between 2006 and 2007, also in Spain. All
patients were diagnosed by clinical neurologists in the
team (M.J.S., B.N., S.B. or A.M.) as having MO (55.9% in
population 1 and 61.4% in population 2) or MA based on
the International Criteria for Headache Disorders 2nd edi-
tion (ICHD-II) [3] after administration of a structured
questionnaire and direct interview and examination.
Patients were recruited from three centers (Hospital Uni-
versitari Vall d'Hebron, HUVH, Barcelona; Hospital Sant
Joan de Déu, Manresa; Fundación Pública Galega de
Medicina Xenómica, FPGMX, Santiago de Compostela).
Patients with hemiplegic migraine, a MA variant usually
showing monogenic inheritance, were excluded. The con-
trol samples consisted of Caucasian Spanish unrelated
adult subjects (blood donors, individuals that underwent
surgery unrelated to migraine or unaffected partners of
migraine patients) that were matched for sex with patients
and recruited in the same geographic areas (HUVH and
FPGMX). Migraine and positive family history of migraine
or any type of severe or recurrent headache in first - degree
relatives were excluded in all control subjects through per-
sonal interview. Genomic DNA was isolated from periph-
eral leukocytes or saliva. Research was approved by the
local Ethics Committees and all the adult participants,
and the children or their parents gave their informed con-
sent prior to participate in the study, according to the Hel-
sinki Declaration.
SNP selection, SNPlex design, genotyping and quality 
control
We selected SNPs in nine candidate genes involved in
dopaminergic neurotransmission. These genes encode
five DA receptors (DRD1,  DRD2,  DRD3,  DRD4  and
DRD5), three enzymes involved in DA degradation
(COMT and DBH) or synthesis (TH), and the DA trans-
porter (SLC6A3 or DAT1; [see Additional File 1]).
In order to ensure a full genetic coverage of these genes
and to minimize redundancy, we used the LD-select soft-
ware [11] and the HapMap database (http://www.hap
map.org; release 20)[12] to evaluate the LD pattern of the
region spanning each candidate gene plus three to five kb
flanking regions. TagSNPs were selected at an r2 threshold
of 0.85 and minimal allele frequency (MAF)>0.15 for
genes with less than 15 tagSNPs and MAF>0.25 for those
genes with 15 or more tagSNPs (COMT,  DBH  and
SLC6A3). A total of 69 tagSNPs (26 in multi-loci bins and
43 singletons) were chosen [see Additional File 1]. Of
these, five did not pass through the SNPlex design pipe-
line. After genotyping, MAF were determined in our con-
trol population 1 [see Additional File 2]. To ensure that no
population stratification was present in the sample, 45
anonymous unlinked SNPs located at least 100 kb distant
from known genes were also analyzed [13] by means of
STRUCTURE [14], FSTAT [15] and the method by Pritch-
ard and Rosenberg [16], as previously described [17].BMC Medical Genetics 2009, 10:95 http://www.biomedcentral.com/1471-2350/10/95
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Genotyping was performed at the Barcelona node of the
National Genotyping Center http://www.cegen.org using
the SNPlex technology [18]. Two CEPH DNA samples
were included in the different genotyping assays, and a
concordance rate of 100% with HapMap data was
obtained. The allelic variants of the SNPs under study
were named on the coding strand of each gene.
Statistical analyses
The minimal statistical power, calculated post hoc in pop-
ulation 1 using the Genetic Power Calculator software
[19], assuming a disease prevalence of 0.12, an odds ratio
(OR) of 1.7, a significance level (α) of 0.05 and a MAF of
0.123, the lowest in control population, was 85% and
decreased to 74% for MO and 68% for MA. Given these
estimates, we decided to begin our study by performing a
joint analysis of the MO and MA groups, and to proceed
to separate analyses of clinical subgroups only if a positive
association was obtained in the whole sample.
Individuals with <40% successful genotypes were
excluded from the analysis; SNPs with >10% missing gen-
otypes were considered as failed; SNPs at r2 > 0.85 from
any other studied SNP or showing deviation from Hardy-
Weinberg equilibrium (HWE; threshold set at 0.01) as cal-
culated in our control population 1 were also excluded.
The SNPs analyzed in the follow-up population were also
in HWE.
Single-marker analysis
The analysis of HWE as well as case-control comparisons
of both allele and genotype frequencies under a codomi-
nant model were performed with the SNPassoc R library
[20] initially in population 1, adjusting by sex. When a
nominal association was identified (P < 0.05), dominant
and recessive models were also analyzed. The significance
threshold under the Bonferroni correction for multiple
testing was set at P < 5e-04 upon consideration of 50 SNPs
analyzed, genotype and allele comparisons and a single
clinical group. Under a False Discovery Rate (FDR) of 10%
the threshold was set at P < 0.0035, using the qvalue R
library [21].
Multiple-marker analysis
Risk haplotypes were assessed in the whole migraine
group (MO + MA) with the UNPHASED software [22],
only for genes showing association in the single-marker
analysis after the Bonferroni or FDR corrections. The best
up to five-marker haplotype was selected as previously
described [17]. Significance was estimated by a 10,000
permutation procedure with UNPHASED [22]. The spe-
cific assignment of haplotypes to individuals was per-
formed independently in cases and controls with the
PHASE 2.0 software [23]. The comparisons of risk haplo-
type carriers vs  non carriers were performed using the
SNPassoc R library [20] adjusting by sex. Subsequently,
risk haplotypes originally identified in the all-migraine
group and SNPs trespassing the FDR threshold were tested
in the MO and MA subgroups.
Follow-up replication study
Risk haplotypes identified in population 1 were tested in
the replication population 2. For SNPs showing nominal
association with migraine in population 1 a comparison
of genotype and allele frequencies was undertaken in pop-
ulation 2.
Results
Initially, 64 SNPs from nine candidate genes encoding
proteins related with DA neurotransmission were geno-
typed [see Additional File 1]. Fourteen SNPs were
excluded from statistical analysis after data depuration in
the first population: ten had genotype call rates <90%,
one was monomorphic and three were in strong LD with
other SNPs (r2 > 0.85, [see Additional File 1]). The 50
remaining SNPs had MAF>0.12 and were in HWE in con-
trol population 1 (P > 0.01; [see Additional File 2]). After
the exclusion of individuals with low genotyping rate,
population 1 consisted of 263 patients and 274 controls,
and population 2 was composed of 259 patients and 287
controls. No evidence of population stratification was
found in any of the two populations studied by applying
the STRUCTURE software [see Additional File 3], the Fst
coefficient (theta = 0, 99%CI = 0.000-0.001 for popula-
tion 1 and theta = 0, 99%CI = 0.000-0.002 for population
2) and the method by Pritchard and Rosenberg (P = 0.57
for population 1 and P = 0.05 for population 2).
In the single-marker analysis, genotype and allele frequen-
cies were compared between patients and controls in pop-
ulation 1 [see Additional File 2]. Six SNPs within five
genes (DRD1, DRD2, DRD3, DBH and TH) displayed P-
values < 0.05 (table 1). Two of them, rs2283265 in DRD2
and rs2070762 in TH, remained significant after applying
a FDR of 10% (Table 1A) and were further considered for
the multiple-marker analysis. No SNP withstood the
restrictive Bonferroni correction for multiple testing. For
these two SNPs we sought to detect a specific association
with either one of the clinical subtypes, MO or MA. We
found that in population 1, DRD2 rs2283265 was associ-
ated wit both MO and MA, while TH rs2070762 was only
associated with MO (Table 1B).
The analysis of all possible allelic combinations within
the  DRD2  gene revealed a five-marker haplotype
(rs12363125-rs2283265-rs2242592-rs1554929-
rs2234689) associated with migraine (best adjusted P-
value = 0.00889; Table 2), with an over-representation of
the T-C-G-C-G allelic combination in cases (OR = 1.85,
95%CI = 1.13-3.04, P = 0.0139) and the C-A-A-C-C hap-
lotype in controls (OR = 1.88, 95%CI = 1.25-2.82, P =
0.00199; Table 3). The T-C-G-C-G haplotype carriers dis-B
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Table 1: Results of dopamine-related genes association studies
A. Significant results of the association study of 50 SNPs from eight dopamine-related genes in population 1 (patients N = 263, controls N = 274) and results of the analysis 
of these markers in population 2 (patients N = 259, controls N = 287).
Cases Controls Genotype
11 vs 
12+22
Genotype 
11+12 vs 22
Allele 2 vs 
allele 1
Gene SNP 
population
11 12 22 Sum 11 12 22 Sum P value OR 
(95% IC)
P value OR 
(95% IC)
P value OR 
(95% IC)
P value
DRD1 rs251937 p1 133 (54.7) 95 (39.1) 15 (6.2) 243 120 (45.5) 119 (45.1) 25 (9.4) 264 NS 1.45a 
(1.02-2.08)
0.0355 1.58a 
(0.82-3.12)
NS 1.36 
(1.04-1.79)
0.0261
p2 130 (53.0) 95 (38.8) 20 (8.2) 245 144 (51.8) 116 (41.7) 18 (6.5) 278 NS 1.05a 
(0.74-1.49)
NS 1.29 
(0.66-2.51)
NS 1.01a 
(0.77-1.33)
NS
DRD2 rs12363125
p1
133 (51.8) 97 (37.7) 27 (10.5) 257 108 (40.6) 128 (48.1) 30 (11.3) 266 0.0304 1.56a 
(1.11-2.22)
0.0102 1.07a 
(0.62-1.85)
NS 1.31 
(1.01-1.70)
0.0401
p2 112 (43.6) 123 (47.9) 22 (8.5) 257 141 (49.5) 112 (39.3) 32 (11.2) 285 NS 1.27 
(0.90-1.78)
NS 1.35a 
(0.76-2.38)
NS 1.07 
(0.83-1.39)
NS
DRD2 rs2283265
p1
210 (82.4) 44 (17.3) 1 (0.3) 255 196 (72.3) 69 (25.5) 6 (2.2) 271 0.0085 1.79a 
(1.18-2.70)
0.0059 5.88a 
(0.68-50)
NS 1.78 
(1.20-2.63)
0.0030*
p2 199 (77.7) 54 (21.1) 3 (1.2) 256 226 (81.3) 49 (17.6) 3 (1.1) 278 NS 1.24 
(0.81-1.89)
NS 1.09 
(0.22-4.46)
NS 1.2a 
(0.81-1.77)
NS
DRD3 rs3732790
p1
113 (44.0) 119 (46.3) 25 (9.7) 257 104 (38.7) 115 (42.7) 50 (18.6) 269 0.0131 1.25a 
(0.88-1.75)
NS 2.12a 
(1.27-3.57)
0.0033 1.36 
(1.06-1.75)
0.0169
p2 101 (39.5) 122 (47.7) 33 (12.8) 256 114 (40.3) 125 (44.2) 44 (15.5) 283 NS 1.03 
(0.73-1.46)
NS 1.25a 
(0.76-2.04)
NS 1.04 
(0.81-1.33)
NS
DBH rs1611131
p1
129 (56.6) 76 (33.3) 23 (10.1) 228 129 (49.6) 114 (43.8) 17 (6.6) 260 0.0400 1.33a 
(0.93-1.92)
NS 1.57 
(0.81-3.02)
NS 1.09 
(0.83-1.47)
NS
p2 124 (51.0) 102 (42.0) 17 (7.0) 243 136 (52.7) 107 (41.5) 15 (5.8) 258 NS 1.07 
(0.76-1.52)
NS 1.22 
(0.60-2.50)
NS 1.08a 
(0.82-1.42)
NS
TH rs2070762
p1
51 (20.8) 138 (56.3) 56 (22.9) 245 84 (32.2) 129 (49.4) 48 (18.4) 261 0.0130 1.81 
(1.21-2.72)
0.0035* 1.32 
(0.85-2.03)
NS 1.37a 
(1.08-1.75)
0.0111
p2 57 (23.4) 119 (49.0) 67 (27.6) 243 78 (28.2) 131 (47.3) 68 (24.5) 277 NS 1.28 
(0.86-1.90)
NS 1.17 
(0.79-1.74)
NS 1.16a 
(0.92-1.49)
NSB
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B. Results of the association study of DRD2 rs2283265 and TH rs2070762 in the migraine without aura and migraine with aura subgroups of population 1 and population 2.
Cases Controls Genotype
11 vs 
12+22
Genotype 
11+12 vs 22
Allele 2 vs 
allele 1
Gene SNP 
population
11 12 22 Sum 11 12 22 Sum P value OR 
(95% IC)
P value OR 
(95% IC)
P value OR 
(95% IC)
P value
Migraine 
without 
aura
DRD2 rs2283265
p1
119 (82.6) 25 (17.4) 0 (0.0) 144 196 (72.3) 69 (25.5) 6 (2.2) 271 0.0097 1.81a 
(1.10-3.03)
0.017 1.02 
(1.004-1.04)
0.023 1.85 
(1.15-2.90)
0.0081
p2 115 (72.8) 40 (25.3) 3 (1.9) 158 226 (81.3) 49 (17.6) 3 (1.1) 278 NS 1.59 
(1.00-2.53)
NS 1.80 
(0.36-9.05)
NS 1.52a 
(1.00-2.32)
NS
TH rs2070762
p1
27 (19.0) 84 (59.2) 31 (21.8) 142 84 (32.2) 129 (49.4) 48 (18.4) 261 0.0143 2.04 
(1.24-3.34)
0.0036 1.24 
(0.74-2.05)
NS 1.40a 
(1.04-1.88)
0.023
p2 37 (24.5) 73 (48.3) 41 (27.2) 151 78 (28.2) 131 (47.3) 68 (24.5) 277 NS 1.19 
(0.76-1.88)
NS 1.11 
(0.71-1.76)
NS 1.11a 
(0.84-1.47)
NS
Migraine 
with 
aura
DRD2 rs2283265
p1
91 (82.0) 19 (17.1) 1 (0.9) 111 196 (72.3) 69 (25.5) 6 (2.2) 271 NS 1.75a 
(1.00-3.03)
0.042 2.5a 
(0.29-20.0)
NS 1.69 
(1.01-2.77)
0.037
p2 84 (85.7) 14 (14.3) 0 (0.0) 98 226 (81.3) 49 (17.6) 3 (1.1) 278 NS 1.37a 
(0.72-2.56)
NS 1.01a 
(0.99-1.02)
NS 1.41 
(0.77-2.63)
NS
TH rs2070762
p1
24 (23.3) 54 (52.4) 25 (24.3) 103 84 (32.2) 129 (49.4) 48 (18.4) 261 NS 1.57 
(0.93-2.66)
NS 1.44 
(0.83-2.5)
NS 1.35a 
(0.98-1.89)
NS
p2 20 (21.7) 46 (50.0) 26 (28.3) 92 78 (28.2) 131 (47.3) 68 (24.5) 277 NS 1.44 
(0.82-2.52)
NS 1.28 
(0.75-2.20)
NS 1.26a 
(0.90-1.75)
NS
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism; NS, no significant; p1: population 1; p2: population 2
a When odds ratio <1, the inverted score is shown.
* Statistically significant P-values after applying a false discovery rate of 10% (p < 0.0035)
rs251937: 1 = A, 2 = G; rs12363125: 1 = A, 2 = G; rs2283265: 1 = G, 2 = T; rs3732790: 1 = A, 2 = G; rs1611131: 1 = T, 2 = C; rs2070762: 1 = T, 2 = C.
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played an OR of 1.74 (95%CI = 1.06-2.88, P = 0.0277). In
order to investigate if the association was specific of MO
or MA, we compared the risk haplotype carrier frequencies
between controls and each migraine subgroup separately.
Although the frequencies were different (10.6% controls,
17.7% MO, 16.4% MA), they only reached borderline sig-
nificance in MO (P = 0.042), while no significant differ-
ences were found in MA (P = 0.12). We performed a
second-stage replication study in an independent Spanish
case-control cohort to test these positive findings. The fre-
quency of the risk haplotype T-C-G-C-G (rs12363125-
rs2283265-rs2242592-rs1554929-rs2234689) carriers in
population 2 was compared between 259 patients and
287 controls. Control carrier frequencies were very similar
to those obtained in population 1 (10.4% control popu-
lation 2 and 10.8% control population 1), whereas case
carriers were more frequent in population 1 (17.1%) than
in population 2 (14.3%). Thereby, the differences
between cases and controls in population 2 did not reach
significance (P = 0.22).
Multiple-marker analysis of the two SNPs (rs6356 and
rs2070762) in TH showed a different overall distribution
between cases and controls (best adjusted P-value =
0.015, Table 2), due to an over-representation the A-C
allelic combination in cases (P = 0.037, OR = 1.34, 95%CI
= 0.94-1.90), and G-T in controls (P = 0.00573, OR = 1.47,
95%IC = 1.11-1.94; Table 3). However, individual haplo-
type assignation did not identify differences in the fre-
quency of risk haplotype carriers between cases and
controls. Moreover, the analysis of rs6356-rs2070762
haplotype distributions in cases and controls of popula-
tion 2 found no evidence of association with migraine
(table 3).
Finally, we aimed to determine whether those variants
nominally associated with the disease phenotype in pop-
ulation 1 after the single-marker analysis, could be repli-
cated in population 2, especially rs2283265 in the DRD2
gene and rs2070762 in the TH gene, which maintained
significance after FDR correction in the initial analysis.
The comparison of genotype and allele frequencies
between cases - either the whole group of migraineurs, or
MO or MA subgroups- and controls did not reveal signifi-
cant differences for rs2283265 (codominant genotypes P
= 0.62 and alleles P = 0.36), rs2070762 (codominant gen-
otypes P = 0.44 and alleles P = 0.22) nor for any other SNP
(table 1).
Discussion
We performed a two-stage case-control association study
of eight dopamine-related genes in the Spanish popula-
tion. In order to capture the common haplotype variation
of these genes in the European population, we selected
haplotype-tagging SNPs which covered each gene and its
flanking regions. In population 1, a five-marker risk hap-
lotype in the DRD2 gene and a single variant in the TH
gene were found to be associated with migraine, and both
remained significant after applying correction for multi-
ple comparisons. In the initial single-marker analysis,
pointing at five genes including the two above, no SNP
withstood the Bonferroni correction. However, it is well
known that this correction is often over-conservative as it
assumes independence of all the tests performed, whereas
many SNPs within the genes studied, although not in
strong LD, are not independent. When markers found
associated in population 1 were analyzed in the follow-up
population, the results could not be replicated. As special
attention was paid to rule out the existence of stratifica-
tion and both populations were comparable in terms of
size, gender distribution, ethnicity (Caucasians), geo-
graphical origin (Spain) and diagnostic criteria, failure to
replicate the results suggests that the associations identi-
fied in population 1 may be spurious and that the genes
analyzed here would not be involved in migraine suscep-
tibility. However, these findings should be taken with cau-
tion, as the genetic coverage of some of the studied genes
is not optimal for several reasons: First, SNPs with low fre-
quencies, which would require very large sample sizes to
produce significant results, were not selected. Second,
some SNPs within the studied genes, for which no LD data
were available in the HapMap database, were not
included. And third, SNPlex design constraints and low
genotyping call rates of some specific SNPs forced addi-
tional exclusions that left the DRD4 gene out of the study.
Of note, the same Spanish cohort analyzed in the present
work was previously scrutinized by us to detect associa-
tion of MA or MO with genes related with serotonin neu-
rotransmission [10]. Among the three genes that
displayed significant association, two belong to the
dopamine metabolic pathway: MAOA, found to be associ-
ated with MO, and DDC, which was associated with MA.
However, these findings still await replication.
A number of association studies have focused on
dopamine-related genes. The first susceptibility polymor-
phism identified in this system was the NcoI variant in the
DRD2 gene (rs6275), with an over-representation of the C
allele in MA [24]. Subsequent studies failed to replicate
this association [25-28] or that with other DRD2 poly-
morphisms [27,29]. It is worth mentioning, however, that
a (TG)n repeat variant in DRD2 was found associated with
yawning and nausea in a small subgroup of migraine
patients [30]. We analyzed DRD2 rs2242592, in strong LD
with rs6275, that belonged to a risk haplotype identified
in population 1 but not confirmed in population 2. Sub-
sequent studies found association between migraine phe-
notypes and polymorphisms in DRD4 [31,32] and DBH
[9,25,33,34], although negative associations have also
been described [9,30,31,33]. No associations have beenBMC Medical Genetics 2009, 10:95 http://www.biomedcentral.com/1471-2350/10/95
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identified in any of the polymorphisms analyzed in genes
DRD1,  DRD3,  DRD5  or  COMT  [9,27,30,35-38]. The
genetic marker set selected in the present analysis is in
many respects not comparable with the polymorphisms
analyzed in the previous studies. However, our results
agree with previous negative findings in DRD1, DRD3 and
one polymorphism in DBH.
A recent study carried in two German populations [9],
analyzed the contribution of the nine dopamine-related
genes we have examined, plus DDC, to MA susceptibility.
In that study, MA was associated with three SNPs, SLC6A3
rs40184, DRD2 rs7131056 and DBH rs2097629. Overall,
they analyzed 43 SNPs belonging to the nine genes stud-
ied in our work; of them, 23 SNPs are coincident or in
strong LD (r2 > 0.85) with the ones we analyzed. The
remaining 20 markers were not included in our analysis
because their MAFs values were under the selected cut off
(n = 13), lacked genotyping in the HapMap sample (n =
3), had SNPlex design constraints (n = 2) or failed in the
genotyping step (n = 2). Conversely, our study included
27 SNPs with MAF>0.15 that were not analyzed by Todt et
al. Three out of five nominal associations identified in our
population 1, not replicated in population 2, also showed
P-values > 0.05 in the first German population, thus rein-
forcing the likelihood of a spurious association in our
population 1. Our study did not reveal association with
rs7131056 in DRD2 or rs40184 in SLC6A3 at variance
Table 2: Haplotype analysis of DRD2 and TH SNPs in 263 migraine patients and 274 unrelated non-migraine controls using the 
UNPHASED software.
Gene Markera Haplotype Global P Best Haplotype-P (Adjusted P-Value) Risk Haplotype-OR
DRD2 6 7 0.00519 0.00178 (0.00450) 1.37 (1.05-1.79)
6 7 8 0.00175 9.74e-04 (0.00400) 1.74 (1.08-2.80)
6 7 8 10 0.00135 0.00100 (0.00460) 1.84 (1.12-3.02)
6 7 8 9 10b 0.00276 0.00199 (0.00889) 1.85 (1.13-3.04)
TH 1 2 0.0283 0.00573 (0.0150) 1.34 (0.94-1.90)
a DRD2: 6- rs12363125; 7- rs2283265; 8- rs2242592; 9- rs1554929; 10- rs2234689; TH: 1- rs6356; 2-rs2070762.
b Best allelic combination (higher OR)
Table 3: Haplotype distributions of DRD2 in populations 1 and 2 using the UNPHASED software.
DRD2
Population 1 Overall P-value = 0.00276 Population 2 Overall P-value = 0.048
Markera Haplotype Cases (%) Controls (%) Haplotype-specific P; OR (CI) Cases (%) Controls (%) Haplotype-specific P
6 7 8 9 10
C C G C G 49 (9.9) 58 (11.5) 0.423 66 (13.9) 47 (9.1) 0.018
C C G C C 47 (10.1) 40 (7.9) 0.233 42 (8.8) 55 (10.7) 0.331
C A A C C 40 (8.6) 76 (15.1) 0.00199; 1.88 (1.25-2.82) c 53 (11.1) 53 (10.3) 0.660
T C G C G 44 (9.4) 27 (5.4) 0.0139; 1.85 (1.13-3.04) 37 (7.8) 28 (5.4) 0.136
T C A T C 287 (62.0) 303 (60.1) 0.581 278 (58.4) 333 (64.5) 0.047
TH
Population 1 Overall P-value = 0.0283 Population 2 Overall P-value = 0.2
Markerb Haplotype Cases (%) Controls (%) Haplotype-specific P; OR (CI) Cases (%) Controls (%) Haplotype-specific P
1 2
A C 82 (17.4) 68 (13.5) 0.0370; 1.34 (0.94-1.90) 100 (20.9) 86 (15.7) 0.129
A T 108 (23.0) 118 (23.7) 0.674 82 (17.2) 123 (22.4) 0.141
G C 162 (34.6) 149 (29.9) 0.127 147 (30.8) 178 (32.5) 0.935
G T 118 (25.0) 165 (32.9) 0.00573; 1.47 (1.11-1.94) c 149 (31.1) 161 (29.4) 0.953
a DRD2: 6- rs12363125; 7- rs2283265; 8- rs2242592; 9- rs1554929; 10- rs2234689
b TH: 1- rs6356; 2- rs2070762
c Under-represented in patients in comparison with control subjectsBMC Medical Genetics 2009, 10:95 http://www.biomedcentral.com/1471-2350/10/95
Page 8 of 9
(page number not for citation purposes)
with the German study, while rs2097629 in DBH was not
included in our study because of design constraints. In
addition to differences in the respective SNP sets, our sam-
ples were composed of both MO and MA patients, and
therefore a comparison of our results with those of Todt et
al. is not altogether straightforward. Also, our analytical
design set that the two population samples could only be
grouped for analysis in case nominal associations were
found in both populations 1 and 2, while in the German
study their two samples were analyzed as a single group
for all SNPs within the three genes that showed nominal
association in only one population. This strategy pro-
duced significant associations despite lack of replication
in their follow-up sample. Future studies combining both
marker sets might help to reconcile these apparently dis-
cordant findings.
Much evidence points to dopamine hypersensitivity in
migraineurs, particularly those displaying the premoni-
tory symptoms of yawning or nausea. In our study, such
specific symptoms could not be analyzed, since they were
not available in the whole sample. To our knowledge, no
well-powered association study has addressed the rela-
tionship between endophenotypes based on dopaminer-
gic symptoms and genetic susceptibility using a pathway-
based approach. Alternatively, latent class analysis of
migraine symptoms, as used to enhance clinical homoge-
neity in genetic linkage analysis [39,40], might define
migraine phenotypes, not necessarily related to ICHD-II
migraine subtype diagnoses, and thus uncover specific
genetic susceptibility factors.
Conclusion
In summary, our results do not support the involvement
of a set of dopamine-related genes in the genetic vulnera-
bility to migraine in the Spanish population, albeit a pre-
vious association study in the same cohort identified DDC
and MAOA as potential susceptibility genes [10]. Further
studies in larger samples or family-based sets may help to
clarify the contribution of dopamine-related genes to
migraine genetic background.
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